Therefore, Zhang et al. suggested that inhibiting CDK-6 may represent a valuable therapeutic strategy for patients harboring a PIT-1 lineage tumor with GNAS mutations or copy number gain [258]. This evidence concerns the gene CDK6 and neoplasm.